###### Strengths and Limitations of this study

-   The main strength of this study is the assessment of smoking cessation in a large contemporary population who were treated with percutaneous coronary intervention and optimal medical therapy, something which has not previously been explored.

-   By using long-term mortality as the primary endpoint, we are able to assess the hazard of persistent smoking and benefit of smoking cessation after an acute coronary syndrome

-   Patients' smoking habits can change over time, and thus our study is limited by the assessment of smoking status at only one time point.

Background {#s1}
==========

Smoking is a well-recognised risk factor for coronary heart disease and accounts for 11% of cardiovascular deaths worldwide.[@R1] Smoking cessation has been consistently associated with a mortality benefit in both stable coronary artery disease and postacute coronary syndromes (ACS).[@R2] Consequently, smoking cessation is one of the cornerstones of secondary prevention.[@R5]

However, the hazard of persistent smoking post-ACS in contemporary cardiology has not been described. Systematic reviews and meta-analysis have predominantly included studies from the prepercutaneous coronary intervention era.[@R2] More recent studies assessing the impact of smoking post -ACS have focused primarily on younger (\<35 years)[@R6] or older populations (\>65 years),[@R7] have had low rates of revascularisation,[@R6] had suboptimal medical management[@R10] or did not assess the impact of smoking cessation.[@R7]

Thus we aimed to assess the impact of persistent smoking or cessation at 30 days post ACS, compared with non-smokers, on survival in patients treated with percutaneous coronary intervention (PCI) and optimal secondary prevention pharmacotherapy.

Methods {#s2}
=======

The study cohort included consecutive patients enrolled in the Melbourne Interventional Group (MIG) registry who underwent their index PCI for management of ACS between January 2005 and November 2013.

The MIG registry is a multicentre PCI registry and has been previously described in detail.[@R13] Briefly, demographic, clinical, procedural and in-hospital outcome data are prospectively recorded on case report forms using standardised definitions for all fields with follow-up performed at 30 days and 12 months.[@R14]

The registry is coordinated by the Centre of Cardiovascular Research and Education in Therapeutics, an independent research body within the School of Public Health and Preventive Medicine at Monash University (Melbourne, Australia). An audit of a number of verifiable fields from 5% of randomly selected procedures at each institution is undertaken periodically.[@R15] In the most recent audit, 27 fields were assessed with data accuracy of 98%. This compares favourably to audits from other large registries.[@R16] The ethics committee in each participating hospital has approved the MIG registry, including the use of 'opt-out' consent. This means that consent is presumed unless the patient 'opts out' after receiving a 'Patient Information Sheet'. If a patient informs a staff member that they do not wish to participate, the patient's data are not collected.

Patients who underwent PCI for ACS and survived to 30 days were included. ACS encompasses the spectrum of ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI) and unstable angina. STEMI was defined as ECG changes (new ST-segment elevation at the J-point or development of Q-waves in two or more contiguous leads) with confirmed myocardial necrosis (elevation in troponin T or I or creatine kinase-MB on at least one occasion within 24 hours from the index event). NSTEMI was defined as biomarker elevation consistent with myocardial necrosis and one of: either ST-segment depression or T-wave abnormality on ECG or ischaemic symptoms. Unstable angina is defined by clinical history suggestive of progressive, unstable ischaemic symptoms without cardiac biomarker elevation.

Acute management of all patients including interventional strategy, stent selection and antithrombotic therapy were left at the discretion of the operator in all procedures. Optimal secondary prevention pharmacotherapy was encouraged according to guidelines. No records were made of contraindications to medications or decisions regarding use/omission of particular guideline-directed therapies.

Patients were divided into four groups based on their smoking status at 30 days. Those who never smoked tobacco were included in the non-smoker group. Those who had quit smoking more than 1 month prior to ACS were classified as ex-smokers. Recent quitters were smokers at baseline but had quit by 30 days. Persistent smokers were smokers at baseline and were still smoking 30 days post-ACS.

The primary outcome was subsequent survival in those patients who were alive at 30 days post-ACS. Survival status was obtained by linkage to the Australian National Death Index (NDI). The Australian NDI is a database housed at the Australian Institute of Health and Welfare, which contains records of all deaths occurring in Australia since 1980. Data are obtained from the registries of births, deaths and marriages in each state and territory. The following variables for each deceased patient were identified: name, date of birth (or estimated year of birth), age at death, gender, date of death, state/territory of registration and registration number. Successful matching of patients through this linkage process was achieved in 99.4% of patients in the MIG registry.

Secondary outcomes were 12-month mortality, MI, stroke and major adverse cardiovascular events (MACCE). Twelve-month MACCE was defined as the combination of mortality, MI, stroke and target vessel revascularisation. MI was defined as an increase in CK or CK-MB ≥3 times the upper limit of normal and/or a significant ST-segment change, development of new Q waves in ≥2 contiguous electrocardiographic leads or new left branch bundle block pattern in the context of new clinical symptoms.

Statistical analysis {#s2a}
--------------------

Continuous variables are expressed as mean ±SD, and categorical data are expressed as numbers/percentages. Continuous variables were compared using Kruskal-Wallis equality-of-populations rank test. Categorical variables were compared using Fisher's exact or Pearson's χ^2^ tests as appropriate. Variables were tested for linear trends across the years 2005--2013 using Stata's *nptrend* command. This is a non-parametric test for trend across ordered groups that is an extension of the Wilcoxon rank-sum test. Cumulative incidence of mortality was estimated by the Kaplan-Meier method and the log-rank test was used to evaluate differences between groups. Cox-proportional hazards regression was used to estimate the adjusted HR and 95% CI for survival. Univariate variables with p\<0.10 were included for stepwise removal for the final multivariate model. The variables considered were: smoking status, age, sex, estimated glomerular filtration rate, hypertension, diabetes, hypercholesterolaemia, family history of coronary disease, previous MI, previous PCI, previous coronary artery bypass graft surgery (CABG), heart failure, peripheral vascular disease, cerebrovascular disease, left ventricular ejection fraction, multivessel CAD, angina type, chronic lung disease, cardiogenic shock, glycoprotein IIb/IIIa use, drug-eluting stent use and treated left main lesion.

All statistical analyses were performed using Stata V.13.1 (StataCorp). p Values \<0.05 were considered to be statistically significant.

Results {#s3}
=======

Of the 9375 survivors following PCI for ACS at 30 days, 2728 (29.1%) had never smoked, 3712 (39.6%) were ex-smokers, 1612 (17.2%) were recent quitters (smokers at the time of ACS but quit by 30 days) and 1323 (14.1%) were persistent smokers. The smoking cessation rate at 30 days post-ACS was 54.9%. Of the patients alive at 12 months, 23% of quitters had relapsed and 71% of persistent smokers continued to smoke ([figure 1](#F1){ref-type="fig"}).

![Smokers at baseline, 30 days and 12 months. \*Includes only those patients alive at 12 months. Recent quitters were smokers at baseline but had quit by 30 days. Persistent smokers were smokers at baseline and were still smoking 30 days and 12 months post acute coronary syndrome. Relapsed smokers were smoking at 12 months although they temporarily quit at 30 days.](bmjopen-2017-016874f01){#F1}

Trends in smoking status {#s3a}
------------------------

[Figure 2](#F2){ref-type="fig"} depicts the trends in smoking status over the 9-year period from 2005 to 2013. The percentage of non-smokers presenting with ACS increased over the time period while the rate of ex-smokers has decreased (p value for trend=0.02). There has been no significant change in the trend of smokers presenting with ACS.

![Trends in smoking status in acute coronary syndrome survivors at 30 days.](bmjopen-2017-016874f02){#F2}

Clinical characteristics {#s3b}
------------------------

Baseline clinical characteristics stratified by smoking status at 30 days are shown in [table 1](#T1){ref-type="table"}. It is evident smokers at the time of ACS (subsequent quitters and persistent smokers) were younger, had less comorbidities but a higher rate of a family history of premature CAD. Compared with quitters, persistent smokers were more likely to have had previously documented CAD (high rates of previous MI/PCI/CABG), peripheral vascular disease and stroke.

###### 

Baseline clinical characteristics N (%) stratified by smoking status at 30 days

  -----------------------------------------------------------------------------------------------------------
                             Non-smoker\   Ex-smoker\    Recent\       Persistent smoker (n=1323)   p Value
                             (n=2728)      (n=3712)      quitter\                                   
                                                         (n=1612)                                   
  -------------------------- ------------- ------------- ------------- ---------------------------- ---------
  Age (mean±SD years)        67.0±12.3     67.0±11.5     56.1±10.2     56.7±10.6                    \<0.001

  Age \>75 years             857 (31.4)    1093 (29.5)   74 (4.6)      82 (6.2)                     \<0.001

  Male                       1753 (64.3)   3038 (81.8)   1310 (81.3)   1028 (77.7)                  \<0.001

  BMI (mean±SD kg/m^2^)      28.0±5.3      28.4±5.1      28.4±5.3      28.2±5.6                     0.004

  Hypertension               1738 (63.7)   2628 (70.8)   752 (46.7)    701 (53.0)                   \<0.001

  Hypercholesterolaemia      1665 (61.1)   2627 (70.8)   895 (55.6)    806 (61.1)                   \<0.001

  Diabetes mellitus          630 (23.1)    1014 (27.3)   216 (13.4)    244 (18.4)                   \<0.001

  Family history of CAD      964 (35.5)    1412 (38.3)   704 (44.1)    554 (42.2)                   \<0.001

  Previous MI                444 (16.3)    1043 (28.1)   183 (11.4)    249 (18.8)                   \<0.001

  Previous PCI               445 (16.3)    884 (23.8)    168 (10.4)    222 (16.8)                   \<0.001

  Previous CABG              159 (5.8)     378 (10.2)    29 (1.8)      43 (3.3)                     \<0.001

  Congestive heart failure   83 (3.0)      167 (4.5)     12 (0.8)      30 (2.3)                     \<0.001

  PVD                        92 (3.4)      313 (8.4)     55 (3.4)      83 (6.3)                     \<0.001

  Stroke                     157 (5.8)     293 (7.9)     46 (2.9)      61 (4.6)                     \<0.001

  Chronic lung disease       166 (6.1)     516 (13.9)    118 (7.3)     170 (12.9)                   \<0.001

  eGFR≥60 mL/min/1.73 m^2^   1970 (74.3)   2726 (74.9)   1384 (89.4)   1135 (88.9)                  \<0.001

  Ejection fraction\>45%     1791 (72.2)   2311 (70.5)   1077 (71.9)   846 (70.6)                   0.61
  -----------------------------------------------------------------------------------------------------------

BMI, body mass index; CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease. 

ACS presentation type, angiographic characteristics and acute outcomes are shown in [table 2](#T2){ref-type="table"}. Smokers at time of ACS were more likely to present with STEMI, have single vessel CAD and receive a bare metal stent. They also had earlier discharge from hospital. The use of secondary prevention pharmacotherapy across all groups is depicted in [table 3](#T3){ref-type="table"}.

###### 

ACS presentation, angiographic characteristics and acute outcomes N (%) by smoking status at 30 days

  ---------------------------------------------------------------------------------------------------------------------
                                        Non-smoker\   Ex-smoker\    Recent\      Persistent smoker (n=1323)   p Value
                                        (n=2728)      (n=3712)      quitter\                                  
                                                                    (n=1612)                                  
  ------------------------------------- ------------- ------------- ------------ ---------------------------- ---------
  STEMI                                 1243 (45.6)   1430 (38.5)   971 (60.2)   615 (46.5)                   

  NSTEMI                                1100 (40.3)   1591 (42.9)   547 (33.9)   559 (42.3)                   

  Unstable angina                       385 (14.1)    691 (18.6)    94 (5.8)     149 (11.3)                   \<0.001

  Multivessel CAD                       1507 (55.3)   2291 (61.8)   806 (50.2)   655 (49.7)                   \<0.001

  Left main disease                     21 (0.8)      55 (1.5)      3 (0.2)      4 (0.3)                      \<0.001

  Balloon angioplasty only              162 (5.9)     236 (6.4)     66 (4.1)     50 (3.8)                     \<0.001

  Bare metal stent                      1356 (49.7)   1949 (52.5)   918 (57.0)   781 (59.0)                   

  Drug eluting stent                    1210 (44.4)   1527 (41.1)   628 (39.0)   492 (37.2)                   \<0.001

  Number of stents inserted (mean±SD)   1.2±0.6       1.2±0.6       1.2±0.6      1.2±0.6                      0.44

  Successful PCI                        2728 (100)    3711 (100)    1612 (100)   1322 (99.9)                  0.42

  New renal impairment                  34 (1.3)      35 (0.9)      10 (0.6)     4 (0.3)                      0.01

  New heart failure                     130 (4.8)     151 (4.1)     53 (3.3)     26 (2.0)                     \<0.001

  Length of stay (mean±SD days)         5.2±5.2       5.2±5.5       4.5±4.1      4.1±3.4                      \<0.001
  ---------------------------------------------------------------------------------------------------------------------

ACS, acute coronary syndrome; CAD, coronary artery disease; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST segment elevation myocardial infarction.

###### 

Cardiovascular pharmacotherapy N (%) at 30 days by smoking status at 30 days

  --------------------------------------------------------------------------------------------------
                    Non-smoker\   Ex-smoker\    Recent\       Persistent smoker (n=1323)   p Value
                    (n=2728)      (n=3712)      quitter\                                   
                                                (n=1612)                                   
  ----------------- ------------- ------------- ------------- ---------------------------- ---------
  Aspirin           2665 (97.7)   3620 (97.5)   1593 (98.8)   1299 (98.2)                  0.02

  P2Y12 inhibitor   2409 (88.3)   3301 (88.9)   1423 (88.3)   1204 (91.0)                  0.06

  Statin            2610 (95.7)   3523 (94.9)   1583 (98.2)   1279 (96.7)                  \<0.001

  Beta-blocker      2328 (85.3)   3019 (81.3)   1380 (85.6)   1120 (84.7)                  \<0.001

  ACE-I/ARB         2313 (84.8)   3105 (83.7)   1381 (85.7)   1070 (80.9)                  0.002

  Warfarin          259 (9.5)     295 (8.0)     111 (6.9)     84 (6.4)                     0.001

  Spironolactone    66 (2.4)      96 (2.6)      11 (0.7)      29 (2.2)                     \<0.001

  Eplerenone        60 (2.2)      67 (1.8)      38 (2.4)      30 (2.3)                     0.49

  Ezetimibe         82 (3.0)      219 (5.9)     34 (2.1)      32 (2.4)                     \<0.001

  Fibrate           27 (1.0)      62 (1.7)      16 (1.0)      20 (1.5)                     0.06
  --------------------------------------------------------------------------------------------------

ACE-I, ACE inhibitor; ARB, angiotensin receptor blocker.

Clinical outcomes {#s3c}
-----------------

Unadjusted survival at mean follow-up of 3.9±2.2 years showed quitters had lower death rates than persistent smokers, non-smokers or ex-smokers (5.3% vs 8.2% vs 9.6% vs 12.1%, respectively; p\<0.001). The full details of 12-month clinical outcomes and survival are shown in [table 4](#T4){ref-type="table"}. On multivariate analysis being an ex-smoker (HR 1.03, 95% CI 0.87 to 1.22) or a quitter (HR 1.27, 95% CI 0.96 to 1.67) was not associated with an increased hazard compared with non-smokers but being a persistent smoker was associated with increased hazard (HR 1.78, 95% CI 1.36 to 2.32) ([table 5](#T5){ref-type="table"} and [figure 3](#F3){ref-type="fig"}). There was no evidence of any violation of the proportional hazards assumption as based on Schoenfeld residuals with a global test of χ^2^=8.34 with 14 df, p=0.784.

![Cox proportional hazard regression survival curve.](bmjopen-2017-016874f03){#F3}

###### 

Clinical outcomes N(%) by smoking status at 30 days

  ----------------------------------------------------------------------------------------------------
                        Non-smoker\   Ex-smoker\   Recent\      Persistent smoker (n=1323)   p Value
                        (n=2728)      (n=3712)     quitter\                                  
                                                   (n=1612)                                  
  --------------------- ------------- ------------ ------------ ---------------------------- ---------
  Long-term mortality   262 (9.6)     450 (12.1)   86 (5.3)     108 (8.2)                    \<0.001

  12 month mortality    50 (1.9)      100 (2.8)    13 (0.9)     18 (1.4)                     \<0.001

  12 month MI           122 (4.7)     222 (6.2)    51 (3.3)     56 (4.5)                     \<0.001

  12 month stroke       28 (1.1)      37 (1.0)     9 (0.6)      9 (0.7)                      0.3

  12 month TVR          182 (7.0)     272 (7.6)    118 (7.7)    65 (5.2)                     0.03

  12 month MACCE        309 (11.9)    488 (13.7)   157 (10.2)   117 (9.3)                    \<0.001
  ----------------------------------------------------------------------------------------------------

MACCE, major adverse cardiovascular events; MI, myocardial infarction; TVR, target vessel revascularisation.

###### 

Estimates of HR and 95% CI of predictors of long-term mortality using Cox-proportional hazards analysis

                                  HR          95% CI         p Value
  ------------------------------- ----------- -------------- ---------
  Unadjusted                                                 
   Non-smoker                     Reference   --             --
   Ex-smoker                      1.21        1.03 to 1.40   0.02
   Recent quitter                 0.51        0.40 to 0.65   \<0.001
   Persistent smoker              0.82        0.65 to 1.03   0.08
  Multivariate analysis                                      
   Non-smoker                     Reference   --             --
   Ex-smoker                      1.03        0.87 to 1.22   0.72
   Quitter                        1.27        0.96 to 1.68   0.10
   Persistent smoker              1.78        1.36 to 2.32   \<0.001
   Age (per year)                 1.07        1.06 to 1.08   \<0.001
   Multivessel CAD                1.43        1.21 to 1.69   \<0.001
   Drug-eluting stent             0.78        0.67 to 0.92   0.002
   eGFR≥60 mL/min/1.73 m^2^       Reference   --             --
   eGFR 30--59 mL/min/1.73 m^2^   1.47        1.24 to 1.73   \<0.001
   eGFR\<30 mL/min/1.73 m^2^      3.83        2.96 to 4.94   \<0.001
   EF\>45%                        Reference   --             --
   EF 30%--45%                    1.55        1.33 to 1.80   \<0.001
   EF\<30%                        1.60        1.12 to 2.29   0.010
   Diabetes mellitus              1.51        1.29 to 1.77   \<0.001
   Periprocedural MI              1.33        1.13 to 1.56   \<0.001
   Peripheral vascular disease    1.65        1.35 to 2.02   \<0.001
   Chronic lung disease           1.73        1.44 to 2.08   \<0.001

CAD, coronary artery disease; EF, ejection fraction; eGFR, estimated glomerular filtration rate; MI, myocardial infarction.

Discussion {#s4}
==========

In a contemporary cohort of patients presenting with ACS and treated with PCI and optimal secondary prevention pharmacotherapy, only 54% of patients stopped smoking by 30 days. Persistent smokers at 30 days post-PCI experienced an almost twofold increase in long-term mortality. Patients who quit smoking had a survival rate at 4 years that was similar to that of a lifelong non-smoker.

Cigarette smoking is a well-established cardiovascular risk factor and continues to be a major preventable cause of death. Ezzati *et al* estimated 11% (1.62 million) of all global cardiovascular deaths in 2000 were attributable to smoking.[@R1] Although the prevalence of smoking in the general population has decreased over the past 50 years in the USA, in our study the proportion of current smokers at time of ACS did not change significantly over 9 years.[@R17] This emphasises the malignant pathophysiological effects of smoking, namely endothelial dysfunction, thrombogenicity and coronary vasoconstriction, which predispose patients to ACS events.[@R18] Indeed, the significant role of smoking in the pathogenesis of ACS is further highlighted by the fact smokers were younger and lower rates of diabetes, hypertension and hypercholesterolaemia.

Smoking cessation is difficult, even after life-threatening events such as acute coronary syndromes. Systematic reviews have reported smoking cessation rates averaging around 50% in patients with coronary heart disease; this is consistent with the rates observed in our study.[@R2] In addition, we found 23% of those who quit smoking at 30 days had relapsed at 12 months highlighting the difficulty of long-term abstinence. The severity of presentation may be a strong trigger to quit as a smoking cessation rate of 74% was reported in one study with STEMI patients alone.[@R10] We also observed this in our study as patients presenting with STEMI were more likely to quit compared with those presenting with NSTEMI or unstable angina. Implementation of smoking cessation strategies is crucial and the index hospitalisation provides a perfect opportunity for this. Indeed a Cochrane review showed that smoking cessation rates were higher if counselling and pharmacotherapy were initiated during hospital admission.[@R19]

The 'smoker's paradox' in patients with acute coronary syndromes suggests there could be potential survival benefit seen in smokers.[@R20] In our study, smokers had lower unadjusted mortality rates at 12 months and long term. However, when accounting for baseline differences in age and comorbidities, smoking status was no longer associated with improved survival, thus suggesting debunking of the 'smoker's paradox'. This is supported by a systematic review showing only studies in the prethrombolytic and thrombolytic era supporting the paradox, while none of the contemporary studies do.[@R20]

The cardiovascular risk associated with smoking appears to dissipate within 3 years of cessation.[@R21] Systematic reviews have shown smoking cessation to be associated with a 35% relative risk reduction in patients with coronary heart disease and up to 46% in those with an MI.[@R2] A limitation of these reviews is the inclusion of a significant proportion of patients from an era preceding percutaneous coronary intervention and optimal secondary prevention pharmacotherapy. More recent studies assessing the impact of smoking status following ACS have had suboptimal rates of revascularisation or medical management.[@R6] Other studies did not assess the hazard of persistent smoking.[@R7] In our study, persistent smoking after ACS was associated with an increased relative mortality risk of 78% at 4 years. The mortality hazard in our study was lower than the one described in a study of STEMI patients by Kinjo *et al* (HR 1.78 vs 2.27). Although their revascularisation rate was high (\>85%), only 30% of patients received statin therapy. Thus, it could be hypothesised that our higher rate of statin therapy may be responsible for our lower long-term mortality risk. What is unquestionable, as observed in our study, is that a substantial residual mortality risk remains in patients who persist with smoking despite optimal contemporary management with PCI and optimal secondary prevention pharmacotherapy. This increased risk is of similar magnitude to those seen from earlier cardiology eras.[@R2]

Encouragingly, smoking cessation is beneficial and by 4 years our cohort of quitters had a mortality hazard approaching that of lifelong non-smokers. This is theoretically plausible as the deleterious hazards of smoking appear to be reversed within this time frame and cardiac risk has been shown to return to baseline.[@R18] Although complete smoking abstinence is difficult, as previously discussed, Gerber *et al* showed that even a five-cigarette a day reduction is associated with an 18% decline in mortality.[@R8] Again this highlights the importance of smoking cessation or even smoking reduction in secondary prevention.

Our study has a number of limitations. First, inherent to all studies assessing the impact of persistent smoking and cessation, the associations described in our study could be attributed, at least partly, to unaccounted or unmeasured variables. In particular, we did not account for the participation in cardiac rehabilitation programme or for smoking cessation strategies used. Second, we have measured smoking status at one time point and even at 12 months there were a significant number of patients who changed their smoking habits and thus were initially misclassified. We chose smoking cessation at 30 days to assess the impact of the admission with ACS and early medical intervention. Third, we ascertained smoking status by self-report. Although it has been shown to correlate with biochemical assessment in a meta-analysis, there is always a potential for misclassification.[@R23] Fourth, we have only included ACS patients treated with PCI which limits the generalisability of our results to this patient population. Fifth, we included repeated admissions as separate cases which raises the possibility of multiple counting. Lastly, we do not collect a detailed smoking history and thus we could not quantify the mortality hazard based on the quantity of cigarettes smoked over a lifetime, nor could we quantify the benefit of cessation based on the time since the last cigarette was smoked. Future research should focus on collecting and analysing this data to more accurately quantify the effect of smoking post ACS.

Conclusion {#s5}
==========

Patients who continued to smoke after an ACS had a nearly twofold mortality hazard while those who quit had comparable survival to a non-smoker. This underscores the importance of smoking cessation in secondary prevention, despite the improvement in management of ACS with percutaneous coronary intervention and optimal medical therapy.
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